Biomarkers in Prediction of AMI

Launched by UNIVERSITY OF TARTU · Jan 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain biological markers in the blood can help doctors better identify a condition called acute mesenteric ischemia (AMI). AMI occurs when there is not enough blood flow to the intestines, which can be serious. The researchers want to find out which combinations of these markers can tell the difference between two types of AMI and how severe the condition is, based on when the patient starts showing symptoms.

To participate in this trial, individuals need to be at least 18 years old and have had an initial decision made by their doctor to look further into potential mesenteric ischemia. However, if someone is under 18, has already been diagnosed with AMI, or has certain other conditions, they will not be eligible. Participants will have their blood tested at different times after their symptoms start, and the information gathered could help improve diagnosis and treatment for future patients with AMI.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Initial decision in favour of further diagnostics of mesenteric ischaemia
• Exclusion Criteria:
• • Age \<18 years
• • Consent declined by patient or next of kin (delayed consent)
• • Chronic mesenteric ischaemia without an acute event
• • Immediate decision for withdrawal of further diagnostics and active treatment
• • Referral from another hospital with already established diagnosis of AMI
• • AMI diagnosed at surgery without previously having been considered